<DOC>
	<DOCNO>NCT01639638</DOCNO>
	<brief_summary>Treatment consider successful difference response reduction affect area 30 % dos compare placebo Patients randomise 1 3 treatment arm 1 . Placebo 2 . CIGB-300 - 5 mg 3 . CIGB-300 - 15 mg A two week screen visit take place assess patient eligibility , least 2 5 target lesion ( area lesion 20 80 mm2 ) , identify . Patients include study randomly assign one three study arm . Treatment consist 3 perilesional application base target lesion every 48 hour window ±24hs . After application potential local systemic adverse event identify monitor . After last application make , weekly clinical evaluation 3 week every two week , week 12 take place . At time , clinical assessment efficacy carry define response treatment . After visit , patient follow every 3 month one year last treatment complete confirm response long-term security CIGB-300 application . At screen , 2 8 week well 6 12 month post-treatment blood study conduct assess safety systemic point view .</brief_summary>
	<brief_title>Recurrent Nonrecurrent Condyloma Treatment</brief_title>
	<detailed_description />
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>1 . Informed consent sign patient 2 . Women clinical diagnosis recurrent non recurrent genital condyloma 3 . Presence condylomatous lesion area external confluent condylomatous lesion le 20 80 mm2 4 . The number warts 2 20 5 . External genital wart perigenital region 6 . Negative pregnancy test 7 . Age 18 65 year inclusive 1 . Having receive surgery treatment , ablative immunomodulator treatment 30 day prior inclusion 2 . Presence genital wart locate cervix , vagina , bladder rectum 3 . Pregnancy lactation 4 . Patients childbearing age use adequate contraception method treatment prevent pregnancy . 5 . Inadequately control chronic disease ( hypertension , diabetes , chronic kidney failure , heart failure , hyperthyroidism , malignant neoplasm , epilepsy , severe mental depression ) 6 . Patients previous diagnosis bleed disorder chronic blood disorder ( von Willebrand disease , haemophilia , leukaemia ) use anticoagulant within 30 day study 7 . Current genital herpes , require application topical antiviral 8 . Immunosuppressive disease , current intake immunosuppressive/ immunomodulatory drug within 30 day study . 9 . Autoimmune Diseases ( Lupus Erythematosus , Rheumatoid Arthritis , Multiple Sclerosis , Diabetes ) 10 . Severe allergy history urticaria , dermatitis persistent bronchitis bronchial asthma 11 . Febrile illness ( temperature great 38ºC ) time within 24 hour prior administration product suspect acute infectious disease clinical examination 12 . Diseases compromise patient 's consciousness ability give inform consent collaborate study 13 . Concomitant skin lesion prevent administration condylomatous lesion propose site 14 . Participating another clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Recurrent non-recurrent genital condyloma</keyword>
</DOC>